More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm Government grant for Ross River virus research

May 10, 2017 at 11:49 PM EDT · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · May 10, 2017 at 11:49 PM EDT

On 6ix: 6ix.com/news/paradigm-government-grant-for-ross-river-virus-research

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Paradigm Biopharmaceuticals Ltd. on 6ix

Story so far

  • Paradigm Update Ross River Virus Clinical TrialMar 7, 2017

Earlier from Paradigm Biopharmaceuticals

  • Paradigm March Quarter Update & Appendix 4CApr 27, 2017
  • Final participant treated in Phase 2 hay fever trialMar 22, 2017
  • Paradigm receives $1.34 million R&D tax incentive rebateMar 21, 2017
  • Paradigm Update Ross River Virus Clinical TrialMar 7, 2017
  • Quarterly Cashflow ReportJan 31, 2017

Later from Paradigm Biopharmaceuticals

  • Paradigms preclinical hay fever trial publishedMay 15, 2017
  • Paradigm Receives Ethics Approval for Ross River TrialMay 21, 2017
  • Hay Fever Trial UpdateJun 15, 2017
  • Paradigm Enters Heart Failure MarketJun 19, 2017
  • Paradigm To Commence Phase 2 Ross River Virus Clinical TrialJul 9, 2017
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer